BRPI0815659A2 - N- (ARYLAMINO) SULPHONAMIDE DERIVATIVES INCLUDING POLYMORPHS AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME - Google Patents
N- (ARYLAMINO) SULPHONAMIDE DERIVATIVES INCLUDING POLYMORPHS AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAMEInfo
- Publication number
- BRPI0815659A2 BRPI0815659A2 BRPI0815659-0A2A BRPI0815659A BRPI0815659A2 BR PI0815659 A2 BRPI0815659 A2 BR PI0815659A2 BR PI0815659 A BRPI0815659 A BR PI0815659A BR PI0815659 A2 BRPI0815659 A2 BR PI0815659A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- arylamino
- compositions
- preparing
- well
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
- A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
- A01N41/04—Sulfonic acids; Derivatives thereof
- A01N41/06—Sulfonic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/830,733 US8101799B2 (en) | 2005-07-21 | 2007-07-30 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
US3446408P | 2008-03-06 | 2008-03-06 | |
US3446608P | 2008-03-06 | 2008-03-06 | |
US4488608P | 2008-04-14 | 2008-04-14 | |
PCT/US2008/071392 WO2009018233A1 (en) | 2007-07-30 | 2008-07-28 | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0815659A2 true BRPI0815659A2 (en) | 2014-09-30 |
Family
ID=40304796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0815659-0A2A BRPI0815659A2 (en) | 2007-07-30 | 2008-07-28 | N- (ARYLAMINO) SULPHONAMIDE DERIVATIVES INCLUDING POLYMORPHS AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP2184984A4 (en) |
JP (3) | JP2010535232A (en) |
KR (3) | KR20150091434A (en) |
CN (2) | CN101808516B (en) |
AP (1) | AP2817A (en) |
AU (2) | AU2008282338B2 (en) |
BR (1) | BRPI0815659A2 (en) |
CA (1) | CA2693390C (en) |
CO (1) | CO6470808A2 (en) |
CR (1) | CR11244A (en) |
DO (1) | DOP2010000045A (en) |
EA (2) | EA032294B1 (en) |
EC (1) | ECSP109910A (en) |
HK (1) | HK1147396A1 (en) |
HN (1) | HN2010000203A (en) |
IL (1) | IL203296A (en) |
MA (1) | MA31881B1 (en) |
MX (1) | MX2010001244A (en) |
NZ (1) | NZ582929A (en) |
PH (1) | PH12015501914A1 (en) |
SV (1) | SV2010003469A (en) |
TN (1) | TN2010000049A1 (en) |
WO (1) | WO2009018233A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
KR20110014149A (en) * | 2008-04-14 | 2011-02-10 | 아디아 바이오사이언스즈 인크. | Compositions and methods for preparing and using same |
KR102437499B1 (en) * | 2008-09-09 | 2022-08-29 | 에프. 호프만-라 로슈 아게 | Polymorphs of acyl sulfonamides |
SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
UY32486A (en) * | 2009-03-11 | 2010-10-29 | Ardea Biosciences Inc | TREATMENT OF CANCER CANCER |
CN102421427B (en) * | 2009-03-11 | 2013-11-06 | 阿迪生物科学公司 | Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers |
ES2534358T3 (en) | 2009-10-13 | 2015-04-21 | Allomek Therapeutics, Llc | Innovative MEK inhibitors useful in the treatment of diseases |
US8962606B2 (en) * | 2009-10-21 | 2015-02-24 | Bayer Intellectual Property Gmbh | Substituted benzosulphonamides |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
CN102020651B (en) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor |
CN102649773A (en) * | 2011-02-23 | 2012-08-29 | 苏州波锐生物医药科技有限公司 | Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor |
JP6363502B2 (en) * | 2011-04-28 | 2018-07-25 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | HSP90 combination therapy |
WO2012163799A1 (en) * | 2011-05-27 | 2012-12-06 | Bayer Intellectual Property Gmbh | Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides |
EP2788378A4 (en) * | 2011-12-09 | 2015-09-09 | Oncomed Pharm Inc | Combination therapy for treatment of cancer |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
BR112014029338A2 (en) * | 2012-05-31 | 2017-06-27 | Bayer Pharma AG | biomarkers for determining the effective response of hepatocellular carcinoma (hcc) treatment |
KR20220093389A (en) * | 2012-06-04 | 2022-07-05 | 파마싸이클릭스 엘엘씨 | Crystalline forms of a bruton's tyrosine kinase inhibitor |
EP2909182B1 (en) * | 2012-10-19 | 2019-12-04 | Array Biopharma Inc. | Preparation of and formulation comprising a mek inhibitor |
US20150265679A1 (en) | 2012-11-02 | 2015-09-24 | The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor |
EP2950885B1 (en) | 2013-02-04 | 2018-11-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
EP2848246A1 (en) | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
EP3185900A4 (en) | 2014-08-25 | 2018-05-02 | Aimmune Therapeutics, Inc. | Egg protein formulations and methods of manufacture thereof |
DK3265084T3 (en) | 2015-03-03 | 2024-02-12 | Pharmacyclics Llc | Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor |
EA201992744A1 (en) * | 2017-06-16 | 2020-05-27 | Бета Фарма, Инк. | PHARMACEUTICAL COMPOSITIONS N- (2- (2- (DIMETHYLAMINO) ETOXY) -4-METOXY-5 - ((4- (1-METHYL-1H-INDOL-3-IL) PYRIMIDIN-2-IL) AMINO) Phenyl) Acrylamide AND HIS SALTS |
CN114364798A (en) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
JP2575590B2 (en) * | 1992-07-31 | 1997-01-29 | 塩野義製薬株式会社 | Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation |
DK0656887T3 (en) * | 1992-08-25 | 1999-07-05 | Searle & Co | Hydroxyethylaminosulfonamides for use as inhibitors of retroviral proteases |
US7115632B1 (en) * | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
EP1144394B1 (en) * | 1999-01-13 | 2005-08-24 | Warner-Lambert Company LLC | 1-heterocycle substituted diarylamines |
GB0003224D0 (en) * | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
JP2005508322A (en) * | 2001-09-24 | 2005-03-31 | ジェシー エル エス オウ | Methods and ingredients for determining the chemosensitized dose of suramin used in combination therapy |
WO2004006909A1 (en) * | 2002-07-17 | 2004-01-22 | Titan Pharmaceuticals, Inc. | Combination of chemotherapeutic drugs for increasing antitumor activity |
RU2005105693A (en) * | 2002-07-30 | 2005-07-10 | Центарис ГмбХ (DE) | APPLICATION OF ALKYLPHOSPHOCHOLINS AND MEDICINAL PRODUCT FOR TREATMENT OF TUMOR DISEASES |
BRPI0607537A2 (en) * | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | nanoparticulate quinazoline derivative formulations |
EP1876167A4 (en) * | 2005-04-22 | 2010-07-07 | Kissei Pharmaceutical | Crystal polymorphism of 4 -{2-ý(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino¨ethoxy}-3-isopropyl-3 ,5 -dimethylbiphenylcarboxylic acid hydrochloride |
DK1912636T3 (en) * | 2005-07-21 | 2014-07-21 | Ardea Biosciences Inc | N- (ARYLAMINO) -SULPHONAMIDE INHIBITORS OF MEK |
JP2007099763A (en) * | 2005-09-08 | 2007-04-19 | Toyama Chem Co Ltd | New crystal of piperacillin sodium-1 hydrate and method for producing the same |
TW200800150A (en) * | 2005-12-21 | 2008-01-01 | Organon Nv | Compounds with medicinal effects due to interaction with the glucocorticoid receptor |
-
2008
- 2008-07-28 MX MX2010001244A patent/MX2010001244A/en active IP Right Grant
- 2008-07-28 AP AP2010005134A patent/AP2817A/en active
- 2008-07-28 KR KR1020157020493A patent/KR20150091434A/en not_active Application Discontinuation
- 2008-07-28 EA EA201400552A patent/EA032294B1/en not_active IP Right Cessation
- 2008-07-28 WO PCT/US2008/071392 patent/WO2009018233A1/en active Application Filing
- 2008-07-28 EA EA201000268A patent/EA020624B1/en not_active IP Right Cessation
- 2008-07-28 KR KR1020147017261A patent/KR20140098185A/en not_active Application Discontinuation
- 2008-07-28 CA CA2693390A patent/CA2693390C/en not_active Expired - Fee Related
- 2008-07-28 CN CN2008801088296A patent/CN101808516B/en not_active Expired - Fee Related
- 2008-07-28 CN CN201310317815.8A patent/CN103479604B/en not_active Expired - Fee Related
- 2008-07-28 AU AU2008282338A patent/AU2008282338B2/en not_active Ceased
- 2008-07-28 BR BRPI0815659-0A2A patent/BRPI0815659A2/en not_active Application Discontinuation
- 2008-07-28 JP JP2010520118A patent/JP2010535232A/en active Pending
- 2008-07-28 EP EP08796733.7A patent/EP2184984A4/en not_active Ceased
- 2008-07-28 NZ NZ582929A patent/NZ582929A/en not_active IP Right Cessation
- 2008-07-28 KR KR1020107004742A patent/KR20100092424A/en active Search and Examination
-
2010
- 2010-01-13 IL IL203296A patent/IL203296A/en not_active IP Right Cessation
- 2010-01-29 CR CR11244A patent/CR11244A/en not_active Application Discontinuation
- 2010-01-29 EC EC2010009910A patent/ECSP109910A/en unknown
- 2010-01-29 TN TNP2010000049A patent/TN2010000049A1/en unknown
- 2010-01-29 DO DO2010000045A patent/DOP2010000045A/en unknown
- 2010-01-29 SV SV2010003469A patent/SV2010003469A/en unknown
- 2010-01-29 CO CO10009526A patent/CO6470808A2/en not_active Application Discontinuation
- 2010-01-29 HN HN2010000203A patent/HN2010000203A/en unknown
- 2010-02-19 MA MA32636A patent/MA31881B1/en unknown
-
2011
- 2011-02-18 HK HK11101625.8A patent/HK1147396A1/en not_active IP Right Cessation
-
2014
- 2014-11-14 JP JP2014231450A patent/JP6309880B2/en not_active Expired - Fee Related
-
2015
- 2015-01-28 AU AU2015200390A patent/AU2015200390B2/en not_active Ceased
- 2015-08-28 PH PH12015501914A patent/PH12015501914A1/en unknown
-
2017
- 2017-02-03 JP JP2017018477A patent/JP2017125021A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0815659A2 (en) | N- (ARYLAMINO) SULPHONAMIDE DERIVATIVES INCLUDING POLYMORPHS AS MEK INHIBITORS AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | |
AU2015200390A1 (en) | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same | |
BRPI0822104A2 (en) | ANTIMICROBIAN COMPOSITIONS AND METHODS FOR THE USE OF THE SAME | |
BRPI0811635A2 (en) | ARILAZOL-2-IL CYANOETHYLAMINE COMPOUNDS, METHODS FOR MAKING THEM AND METHODS FOR THE USE OF THEM | |
BRPI0813237A2 (en) | COMPOUND, METHOD FOR PREPARING COMPOUND, COMPOSITION, MEDICINE, AND, USE OF COMPOUND. | |
BRPI0818003A2 (en) | csf-1r inhibitors, compositions and methods of use | |
UY33132A (en) | SOLUBLE PROTEINS FOR THERAPEUTIC USE | |
BRPI1010775A2 (en) | composition, method for preparing a composition, and use of a composition. | |
BRPI0918359A2 (en) | compound, agrochemical composition, use of agrochemical composition and method for preparation of compound | |
BRPI0813627A2 (en) | ANTIMICROBIAN PEPTIDIA, COMPOSITIONS AND METHODS OF USE | |
CR10743A (en) | DERIVATIVES OF AZAADAMANTANO AND METHODS OF USE OF THE SAME | |
CO7020907A2 (en) | Quinurenine-3-monooxygenase inhibitors, pharmaceutical compositions and methods of use thereof | |
DK2344486T3 (en) | Alkylthiazole carbamate derivatives, their preparation and their use as inhibitors of the enzyme FAAH | |
BRPI0812159A2 (en) | csf-1r inhibitors, compositions and methods of use | |
BRPI0808813A2 (en) | method for the preparation of rubber compounds, and use of compounds | |
BRPI0812909A2 (en) | POLICYCLIC GUANINE DERIVATIVES AND METHODS OF USE THEREOF. | |
BRPI0910179A2 (en) | amine compound, pharmaceutical composition and use of amine compound | |
CU23744B7 (en) | TETRAHYDRONAFTALINE DERIVATIVES AND PROCEDURES TO PREPARE THEM. | |
BRPI0920862A2 (en) | composition, method of manufacture, and use thereof | |
BRPI0818459A2 (en) | Pharmaceutical composition suitable for ophthalmic use. | |
BR112012004173A2 (en) | "compound, composition, method for preparing a composition, and use of a compound" | |
UY29434A1 (en) | DERIVATIVES OF TETRAHYDRONAFTALINE, PROCEDURES FOR THEIR PREPARATION AND ITS USE AS INFLAMMATION INHIBITORS | |
CL2013002026A1 (en) | Solid compound (r) -1-ethyl-3- [5- [2- (1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl] -7- (tetrahydrofuran-2-yl) -1h-benzimidazole- 2-yl] -urea and method to prepare it. | |
BRPI1012047A2 (en) | oxazolidinone-containing dimer compounds, compositions and methods for making and using | |
BRPI0915391A2 (en) | shale stabilization copolymer and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: ARDEA BIOSCIENCES, INC. (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |